Zhao, Yang BCs*,†; Guo, Yu-Jiao MCs*; Chen, Xiang-Long BCs*; Yang, Yan-Ling BCs*,†; Ma, Hong BCs*; Wang, Yong-Qing PhD*,†; Sun, Lu-Ning PhD*,†
*Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing, China; and
†School of Pharmacy, Nanjing Medical University, Nanjing, China.
Correspondence: Yong-Qing Wang, PhD, Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China (e-mail: [email protected]). Correspondence: Lu-Ning Sun, PhD, Research Division of Clinical Pharmacology, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China (e-mail: [email protected]).
Supported by the Outstanding Young and Middle-aged Talents Support Program of the First Affiliated Hospital of Nanjing Medical University (grant number YNRCQN025) and the establishment of molecularly targeted drug adverse reactions based on artificial intelligence technology (grant number JSHD2021004).
The authors declare no conflict of interest.
Y. Zhao and Y.-J. Guo share the co-first author.
Therapeutic Drug Monitoring ():10.1097/FTD.0000000000001106, May 5, 2023. | DOI: 10.1097/FTD.0000000000001106
